GERON CORP Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses (Deprecated 2013-01-31)
GERON CORP (GERN) had Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses (Deprecated 2013-01-31) of $9.00 thousand as of 2012-09-30, per its 10-Q filed 2012-11-02.
Discontinued › Notes › Investments
us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses2 · last filed 2013-03-15
- 2012-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses (Deprecated 2013-01-31) $9.00K.
- 2012-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses (Deprecated 2013-01-31) $20.00K.
- 2011-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses (Deprecated 2013-01-31) $55.00K.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses (Deprecated 2013-01-31) |
|---|---|
| 2012-09-30 | $9.00K 10-Q · filed 2012-11-02 |
| 2012-06-30 | $20.00K 10-Q · filed 2012-08-03 |
| 2011-12-31 | $55.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |